The United Kingdom's publicly financed National Health Service has granted near-veto power over drug reimbursement decisions to the National Institute for Health and Clinical Excellence, an independent organization known as NICE. As a result, British health authorities are expected to adopt or deny new medical technology based on NICE's assessment of the benefits of this technology versus its impact on health-care costs. This process and the resulting delay in coverage have generated intense controversy in the UK. At the same time, NICE's operation has aroused interest in constructing a similar mechanism in the United States. At this conference, Andrea Sutcliffe, deputy chief executive of NICE, a group of British and American analysts, and an American biomedical industry representative will examine NICE’s method and its implications for U.S. policy.
What's new on AEI
|Rebuilding American defense: A speech by Governor Bobby Jindal|
|Smelling liberal, thinking conservative|
|Stopping Ebola before it turns into a pandemic|
|All too many reasons for pessimism about Europe|
We welcome you to join us for a panel discussion of the undersea military competition occurring in Asia and what it means for the United States and its allies.
AEI’s Election Watch is back! Please join us for two sessions of the longest-running election program in Washington, DC.
We welcome you to join us at AEI for a discussion of what’s next for the Common Core.
Please join AEI for a discussion examining each candidate’s platform and prospects for victory and the impact that a possible shift toward free-market policies in Brazil might have on South America as a whole.